FILING ANALYSIS · FRIDAY, NOVEMBER 13
Fortress Biotech, Inc. FBIO — 8-K: Results of Operations and Financial Condition
neutral
Fortress Biotech reported a 9% increase in total net revenue to $19.2 million for the third quarter of 2026 and repaid its credit facility in full, also announcing a license agreement for FB-607, a novel therapy for irritable bowel syndrome with diarrhea
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →